Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.35 |
| ▸ | MTOR | P42345 | 14/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24956792 | 1.00 | PDE10A (0.35) | PDE10APIK3CAMTORPIK3CG | |
| SCHEMBL30202075 | 0.91 | PDE10A (0.37) | PDE10APIK3CAMTOR | |
| SCHEMBL24956793 | 0.87 | MTOR (0.41) | PDE10APIK3CAMTOR | |
| SCHEMBL24956794 | 0.87 | PDE10A (0.37) | PDE10APIK3CAMTOR | |
| SCHEMBL30202391 | 0.87 | PDE10A (0.35) | PDE10APIK3CAMTOR | |
| SCHEMBL24955663 | 0.84 | DGAT1 (0.37) | PIK3CAMTORPIK3CG | |
| SCHEMBL24956795 | 0.83 | PIK3CA (0.48) | PIK3CAMTORPIK3CG | |
| SCHEMBL24956764 | 0.82 | PIK3CA (0.37) | PIK3CAMTORPIK3CG | |
| SCHEMBL24955686 | 0.81 | PDE10A (0.38) | PDE10APIK3CA | |
| SCHEMBL30202390 | 0.81 | PDE10A (0.38) | PDE10APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377313-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | BenevolentAI Cambridge Limited (GB) | 2024-06-05 | — | — | EP | claimed |
| WO-2023007185-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | claimed |
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
| EP-4377313-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | BenevolentAI Cambridge Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023007185-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | PDE10A 733/4885PIK3CA 2011/4885MTOR 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.